Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

A clinical trial in patients with glioblastoma shows increased immune and anti-tumour responses to dendritic cell vaccination after pre-conditioning the site of vaccination with tetanus toxoid (Td); similar results are also seen in mice in part due to the actions of the chemokine CCL3, and the findings may represent new ways to improve the efficacy of anti-cancer vaccines. John Sampson and colleagues report on a small clinical trial in...